Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics Inc (AVTE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.032x
Based on the latest financial reports, Aerovate Therapeutics Inc (AVTE) has a cash flow conversion efficiency ratio of -0.032x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($75.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aerovate Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Aerovate Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aerovate Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aerovate Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GoldON Resources Ltd
PINK:NCMBF
|
-0.061x |
|
BIL Vyapar Limited
NSE:BILVYAPAR
|
N/A |
|
Arcadia Minerals Ltd
AU:AM7
|
-0.016x |
|
Site Group International Ltd
AU:SIT
|
0.088x |
|
Synergy Empire Limited
PINK:SHMY
|
0.149x |
|
Nexion Group Ltd
AU:NNG
|
0.183x |
|
Standard Supply A/S
OL:STSU
|
-0.641x |
|
Howmet Aerospace Inc. $3.75 Cum. Pfd.
NYSE MKT:HWMPR
|
N/A |
Annual Cash Flow Conversion Efficiency for Aerovate Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Aerovate Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | -126.98% |
| 2020-12-31 | $-13.34 Million | $-7.86 Million | 0.589x | -22.85% |
| 2019-12-31 | $-3.64 Million | $-2.78 Million | 0.763x | -- |